Integrated Care for Migraine and Chronic Tension-type Headaches
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Chronic Headache
- Sponsor
- Universität Duisburg-Essen
- Enrollment
- 158
- Locations
- 1
- Primary Endpoint
- Headache frequency
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
Chronic headache is among the most common neurological disorders with major physical, psychological, social and economic impact. The aim of this prospective observational study isto investigate the effects of an interdisciplinary multimodal integrated care program in patients with chronic migraine and/or tension-type headache.
158 patients with chronic migraine or tensions-type headache at least five days per month for at least 6 months and current intake of triptans (migraine) or analgesic drugs (tension-type headache) are eligible. Patients undergo inpatient, outpatient and/or semi-stationary treatment including conventional headache diagnostics and therapy as well as traditional Chinese medicine, European naturopathy, and mind-body-medicine approaches. Headache frequency is defined as the primary outcome; secondary outcomes include pain (visual analog scale, Pain Perception Scale), triptans and analgesics use (headache diary), health-related quality of life (SF-36), function (Headache Disability Inventory, Patient-specific Functional Scale), depression and anxiety (Hospital Anxiety and Depression Scale), and pain self-efficacy (Pain Self-Efficacy Questionnaire). Outcomes are assessed at treatment start, treatment end and 6 months after treatment end.
Detailed Description
Chronic headache is among the most common neurological disorders with major physical, psychological, social and economic impact. The aim of this prospective observational study isto investigate the effects of an interdisciplinary multimodal integrated care program in patients with chronic migraine and/or tension-type headache. 158 patients with chronic migraine or tensions-type headache at least five days per month for at least 6 months and current intake of triptans (migraine) or analgesic drugs (tension-type headache) are eligible. Patients undergo inpatient, outpatient and/or semi-stationary treatment including conventional headache diagnostics and therapy as well as traditional Chinese medicine, European naturopathy, and mind-body-medicine approaches. Headache frequency is defined as the primary outcome; secondary outcomes include pain (visual analog scale, Pain Perception Scale), triptans and analgesics use (headache diary), health-related quality of life (SF-36), function (Headache Disability Inventory, Patient-specific Functional Scale), depression and anxiety (Hospital Anxiety and Depression Scale), and pain self-efficacy (Pain Self-Efficacy Questionnaire). Outcomes are assessed at treatment start, treatment end and 6 months after treatment end.
Investigators
Holger Cramer
Research Director
Universität Duisburg-Essen
Eligibility Criteria
Inclusion Criteria
- •headache at least five days per month for at least 6 months current intake of a) at least 10 triptans per month or b) analgesic drugs that can themselves elicit headache
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Headache frequency
Time Frame: Treatment end, an average of 5 months
Headache days/month
Secondary Outcomes
- Pain perception(6 months after treatment end)
- Function(6 months after treatment end)
- Pain bothersomeness(6 months after treatment end)
- Headache frequency(6 months after treatment end)
- Self-Efficacy(6 months after treatment end)
- Pain intensity(6 months after treatment end)
- Quality of life(6 months after treatment end)
- Headache Disability(6 months after treatment end)
- Anxiety/Depression Scale(6 months after treatment end)